Intriguingly, SU11248 shows synergistic effects with cytarabine or daunorubicin in inhibiting proliferation and survival of primary AML myeloblasts expressing mutant FLT3/ITD, FLT3/D835V, or FLT3/WT [31]. This evidence concerns the gene FLT3 and acute myeloid leukemia.